ERBB2 and breast carcinoma: The 26 included studies contained a total of 4497 patients, of whom 2273 had HR+/HER2− tumors, 1156 HR+/HER2+, 1068 HR−/HER2+ and 1658 were diagnosed with HR−/HER2-breast cancer.